AGP Executive Report
Last update: 6 hours agoCBD Research: A small knee-replacement trial found patients given 400 mg of prescription CBD used fewer opioids and reported less pain over 72 hours. The 800 mg dose showed no similar benefit, and researchers say larger studies are needed. Hemp Policy: A bipartisan bill would replace an approaching federal ban on most intoxicating hemp products with age limits, product restrictions and FDA oversight. Separately, medical cannabis companies say new DEA guidance could disrupt state-regulated markets. Medical Cannabis: UK registry data found patients with insomnia reported better sleep for up to two years after using prescribed cannabis products. In New Zealand, stigma has eased, but cost and doubts about GP prescribing remain barriers. Patient Access: Boots has launched a private medical cannabis service in the UK, offering another route for patients with long-term conditions.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.